Ugrás a tartalomra
Merck

M7571

Sigma-Aldrich

MK-571 sodium salt hydrate

≥95% (HPLC), powder, leukotriene D4 antagonist

Szinonimák:

5-(3-(2-(7-Chloroquinolin-2-yl)ethenyl)phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoic acid sodium salt hydrate, L-660711

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez


About This Item

Tapasztalati képlet (Hill-képlet):
C26H26ClN2NaO3S2 · xH2O
CAS-szám:
Molekulatömeg:
537.07 (anhydrous basis)
MDL-szám:
UNSPSC kód:
51111800
PubChem Substance ID:
NACRES:
NA.77

product name

MK-571 sodium salt hydrate, ≥95% (HPLC)

Minőségi szint

Teszt

≥95% (HPLC)

form

powder

tárolási körülmény

desiccated

szín

white to beige

oldhatóság

H2O: 15 mg/mL, clear

kezdeményező

Merck & Co., Inc., Kenilworth, NJ, U.S.

kiszállítva

wet ice

tárolási hőmérséklet

−20°C

SMILES string

O.[Na+].CN(C)C(=O)CCSC(SCCC([O-])=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1

InChI

1S/C26H27ClN2O3S2.Na.H2O/c1-29(2)24(30)12-14-33-26(34-15-13-25(31)32)20-5-3-4-18(16-20)6-10-22-11-8-19-7-9-21(27)17-23(19)28-22;;/h3-11,16-17,26H,12-15H2,1-2H3,(H,31,32);;1H2/q;+1;/p-1/b10-6+;;

Nemzetközi kémiai azonosító kulcs

MSHRPLRGSQECLY-DOLBFOAYSA-M

Alkalmazás

MK-571 sodium salt hydrate has been used:
  • as an efflux inhibitor for monitoring multidrug resistance protein (MRP)-function and to avoid redundancy of other transporters
  • to assess its effect on cell proliferation and 2D-migration in vitro in various cell lines of glioblastoma multiforme (GBM)
  • as multidrug resistance (MDR) transporter inhibitor to study its effects in ovarian cancer cells
  • as specific inhibitors of ABCC1/2 to investigate transport, toxicity, flow cytometry and arsenic efflux

Biokémiai/fiziológiai hatások

MK 571 is a potent and selective leukotriene D4 (LTD4) antagonist and ABCC multidrug resistance protein 1(MRP1) inhibitor. The cysteinyl leukotrienes (CysLTs), LTC4, LTD4, and LTE4, mediate their actions through two distinct G-protein coupled receptors. LTD4 is the preferred ligand for the CysLT1 receptor, whereas LTC4 and LTD4 bind with approximately equal affinity to the CysLT2 receptor. MK 571 is a selective, orally active CysLT1 receptor antagonist. It blocks the binding of LTD4, but not LTC4, to human and guinea pig lung membranes with Ki values of 0.22 nM and 2.1 nM, respectively. MK 571 effectively blocks LTD4 activation of recombinant human and mouse CysLT1 receptors but is ineffective at blocking LTC4 or LTD4 activation of the recombinant human or murine CysLT2 receptors. It potentially inhibits MRP1 and has been shown to overcome acquired arsenic tolerance.

Tulajdonságok és előnyök

This compound is featured on the Leukotriene Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramok

Exclamation mark

Figyelmeztetés

Warning

Figyelmeztető mondatok

Veszélyességi osztályok

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Célzott szervek

Respiratory system

Tárolási osztály kódja

11 - Combustible Solids

WGK

WGK 3

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable

Egyéni védőeszköz

dust mask type N95 (US), Eyeshields, Gloves


Analitikai tanúsítványok (COA)

Analitikai tanúsítványok (COA) keresése a termék sarzs-/tételszámának megadásával. A sarzs- és tételszámok a termék címkéjén találhatók, a „Lot” vagy „Batch” szavak után.

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Ethan S Lippmann et al.
Scientific reports, 4, 4160-4160 (2014-02-25)
Blood-brain barrier (BBB) models are often used to investigate BBB function and screen brain-penetrating therapeutics, but it has been difficult to construct a human model that possesses an optimal BBB phenotype and is readily scalable. To address this challenge, we
Hye-Sik Kong et al.
Pharmaceutical research, 29(12), 3373-3383 (2012-07-28)
The HDAC shuttling inhibitor, YK-4-272 functions by restricting nuclear shuttling of Class II HDACs. Pre-clinical investigations of YK-4-272 bioavailability, pharmacokinetics, in vivo toxicity and tumor growth inhibition were performed to determine its potential as an HDAC shuttling disruptor for use
Ascites increases expression/function of multidrug resistance proteins in ovarian cancer cells
Mo L, et al.
Testing, 10(7), e0131579-e0131579 (2015)
Hui-fang Su et al.
Acta pharmacologica Sinica, 37(4), 545-554 (2016-03-15)
(+)-Catechin and puerarin are polyphenol and flavonoid, respectively, in green tea and foodstuffs. They exhibit potent antioxidant activity and are widely used for treating cardiocerebrovascular diseases. The aim of this work was to investigate the potential interactions between (+)-catechin and
Winfried Neuhaus et al.
Frontiers in cellular neuroscience, 8, 352-352 (2014-11-13)
Stabilization of the blood-brain barrier during and after stroke can lead to less adverse outcome. For elucidation of underlying mechanisms and development of novel therapeutic strategies validated in vitro disease models of the blood-brain barrier could be very helpful. To

Cikkek

We offer many products related to leukotriene receptors for your research needs.

Discover Bioactive Small Molecules for Lipid Signaling Research

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással